Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan in HER2+ metastatic breast cancer (DESTINY-Breast02)
NCT03523585Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Jun 2022
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in breast cancer (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression-Free Survival at 46 months. Started Aug 2018; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03523585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523585.